Table 1.
displays currently active or recently completed clinical trials in HPV-associated OPSCC (adapted from https://clinicaltrials.gov)
| NCT Number | Title | Interventions | |
|---|---|---|---|
| 1 | NCT03656133 | Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers |
• Radiotherapy fractionation |
| 2 | NCT03618134 | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner |
• Durvalumab • Modified Radical Neck Dissection • Transoral Robotic Surgery • Tremelimumab |
| 3 | NCT03580070 | Changes in the Microenvironment of HPV-induced Head and Neck Cancers in West Indies and Metropolitan Population |
• Immunotherapy |
| 4 | NCT03578406 | HPV-E6-Specific TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer |
• HPV E6-specific TCR-T cells |
| 5 | NCT03418480 | HPV Anti-CD40 RNA Vaccine | • HPV vaccine |
| 6 | NCT03396718 | De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas |
• De-escalation radio(chemo)therapy - Levels 1 and 2 |
| 7 | NCT03342911 | Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | • Paclitaxel, Carboplatin, Nivolumab |
| 8 | NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers and Expansion Cohort to Oropharyngeal SCCHN | • TG4001, Avelumab |
| 9 | NCT03224000 | Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer | • Modified Barium Swallow, MRI Guided Intensity Modulated Radiotherapy |
| 10 | NCT03162224 | Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer |
• MEDI0457, CELLECTRA®5P device, Durvalumab |
| 11 | NCT03107182 | Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer |
•Carboplatin, Nivolumab, Cisplatin, Hydroxyurea, 5-FU, Dexamethasone, Famotidine, Diphenhydramine, Paclitaxel |
| 12 | NCT03077243 | P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC |
• Intensity Modulated Radiotherapy, Cisplatin (or alternative) |
| 13 | NCT02945631 | Quarterback 2 - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer |
• Radiation: PTV56 |
| 14 | NCT02865135 | Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer |
• DPX-E7 vaccine |
| 15 | NCT02827838 | Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer |
• Durvalumab |
| 16 | NCT02784288 | Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV + Oropharyngeal Squamous Cell Cancer |
•Radiation, Carboplatin, Paclitaxel |
| 17 | NCT02706691 | BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer | •BGJ398 |
| 18 | NCT02686008 | Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC | • Olaparib |
| 19 | NCT02643550 | Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
• Monalizumab, Cetuximab |
| 20 | NCT02281955 | De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study |
• Radiation, cisplatin |
| 21 | NCT02215265 | Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS) |
• Cisplatin, Postoperative radiotherapy |
| 22 | NCT02178072 | Window Trial 5-aza in HNSCC, T-tare | • 5-Azacitadine |
| 23 | NCT02113878 | Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck |
• BKM120, Cisplatin, Intensity-modulated radiotherapy |
| 24 | NCT02002182 | ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer |
• ADXS11–001 (ADXS-HPV) |
| 25 | NCT01716195 | Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer | • Radiotherapy |
| 26 | NCT01706939 | The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer | • Reduced Dose Radiation, Carboplatin |
| 27 | NCT01530997 | De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca |
• Intensity Modulated Radiotherapy, Cisplatin |
| 28 | NCT01302834 | Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer |
• cetuximab, cisplatin |